EUVIMEDEUVIMED entdecken
Crossref

Peri‐Operative Detection of Circulating Tumor DNA Using a Customized NGS Tumor‐Informed Assay in Patients With HPV ‐Negative Locally Advanced Head and Neck Squamous Cell Carcinoma

Ludivine Beaussire-Trouvay iD, Franchel-Raïs Obongo-Anga, Emilie Lévêque, Anca Berghian, Arnaud François, Nicolas Bon-Mardion, Elise Meret, Sophie Deneuve, Elodie Bohers, Mathieu Viennot, Lucie Burel, Julie Libraire und 4 weitere

International Journal of Cancer · 01.08.2026 · 159 (3) · 645-654

DOI: 10.1002/ijc.70478 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 10.04.2026. Verfasst von Ludivine Beaussire-Trouvay und 15 weiteren Autor:innen. Beteiligte Einrichtung: Normandie Univ, UNIROUEN, Inserm U1245, IRON Group, Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, Rouen, France. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Circulating Tumor DNA, Head and Neck Neoplasms, High-Throughput Nucleotide Sequencing. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: canceropole nord ouest, Centre Henri Becquerel.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ctDNA is a promising tool to optimize therapeutic strategies in patients treated for locally advanced head and neck cancer that is negative for Human Papilloma Virus (LAHNSCC/HPV−). The objective was to evaluate pre and postoperative detection of circulating tumor DNA (ctDNA) using a customized Next‐Generation Sequencing (NGS) tumor‐informed assay. We conducted a prospective study including patients treated with initial surgery for a LAHNSCC/HPV−. We developed an NGS assay covering the exons of 11 genes for tumor and ctDNA analysis. DNA alterations were interpreted according to two classes of variants: “ pathogenic variants ” classified as class 4 or 5 in public databases and “tumor specific variants” corresponding to alterations detected exclusively in tumor DNA after paired analysis of normal cell DNA using the same NGS panel. A total of 40 patients were included, 45% with T4 and 62.5% with N + disease. Regarding tumor profiles, 41 “pathogenic variants” were detected corresponding to 30/36 (83.3%) of informative tumors with at least one alteration. In contrast, 354 “tumor specific variants” were identified with at least one alteration in 35/35 (100%) informative tumors. For ctDNA, the NGS panel was associated with a positivity rate of 74.3% and 37.1% pre and postoperative, respectively, using tumor specific variants; compared with 20% and 2.5% using interpretation of pathogenic variant. Pretreatment ctDNA positivity according to pathogenic variant was associated with lower specific progression‐free survival ( p = 0.025). Our customized 11‐genes NGS panel tumor‐informed assay provides high rates of ctDNA detection and may be used to evaluate new strategies in LA HNSCC/HPV− patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorCirculating Tumor DNAHead and Neck NeoplasmsHigh-Throughput Nucleotide SequencingSquamous Cell Carcinoma of Head and NeckAdultAgedFemaleHumansMaleMiddle AgedHuman Papillomavirus VirusesProspective Studies

Stichwörter der Autor:innen

HPV‐negativecirculating tumor DNAcustomized NGS tumor‐informed assaylocally advanced head and neck squamous cell carcinoma

Substanzen

Biomarkers, TumorCirculating Tumor DNA

Autor:innen und Institutionen

  • Normandie Univ, UNIROUEN, Inserm U1245, IRON Group, Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, Rouen, France.
  • Department of Head and Neck Cancer and ENT Surgery, Henri Becquerel Cancer Center, Rouen, France.
  • Department of Statistics and Clinical Research Unit, Henri Becquerel Cancer Center, Rouen, France.
  • Department of Biopathology, Henri Becquerel Cancer Center, Rouen, France.
  • Department of Pathology, Rouen University Hospital, Rouen, France.
  • Department of Head and Neck Surgery, Rouen University Hospital, Rouen, France.

ORCID-Profile: Ludivine Beaussire-Trouvay, Nasrin Sarafan-Vasseur

Förderung

  • canceropole nord ouest
  • Centre Henri Becquerel

Zitieren

APA

Beaussire-Trouvay, L., Obongo-Anga, F. R., Lévêque, E., Berghian, A., François, A., Bon-Mardion, N., Meret, E., Deneuve, S., Bohers, E., Viennot, M., Burel, L., Libraire, J., Libert, L., Sarafan-Vasseur, N., Di Fiore, F., & Clatot, F. (2026). Peri‐Operative Detection of Circulating Tumor DNA Using a Customized NGS Tumor‐Informed Assay in Patients With HPV ‐Negative Locally Advanced Head and Neck Squamous Cell Carcinoma. International Journal of Cancer, 159(3), 645-654. https://doi.org/10.1002/ijc.70478

Vancouver

Beaussire-Trouvay L, Obongo-Anga FR, Lévêque E, Berghian A, François A, Bon-Mardion N, et al. Peri‐Operative Detection of Circulating Tumor DNA Using a Customized NGS Tumor‐Informed Assay in Patients With HPV ‐Negative Locally Advanced Head and Neck Squamous Cell Carcinoma. International Journal of Cancer. 2026;159(3):645-654. doi:10.1002/ijc.70478

BibTeX
@article{BeaussireTrouvay2026,
  author = {Beaussire-Trouvay, Ludivine and Obongo-Anga, Franchel-Raïs and Lévêque, Emilie and Berghian, Anca and François, Arnaud and Bon-Mardion, Nicolas and Meret, Elise and Deneuve, Sophie and Bohers, Elodie and Viennot, Mathieu and Burel, Lucie and Libraire, Julie and Libert, Louise and Sarafan-Vasseur, Nasrin and Di Fiore, Frédéric and Clatot, Florian},
  title = {Peri‐Operative Detection of Circulating Tumor DNA Using a Customized NGS Tumor‐Informed Assay in Patients With HPV ‐Negative Locally Advanced Head and Neck Squamous Cell Carcinoma},
  journal = {International Journal of Cancer},
  year = {2026},
  volume = {159},
  number = {3},
  pages = {645--654},
  doi = {10.1002/ijc.70478}
}
Kostenlos starten →